- Home
- LXRX vs AVIR Comparison
LXRX vs AVIR Comparison
Compare LXRX & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXRX
- AVIR
- Stock Information
- Founded
- LXRX 1995
- AVIR 2012
- Country
- LXRX United States
- AVIR United States
- Employees
- LXRX N/A
- AVIR N/A
- Industry
- LXRX Biotechnology: Pharmaceutical Preparations
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- LXRX Health Care
- AVIR Health Care
- Exchange
- LXRX Nasdaq
- AVIR Nasdaq
- Market Cap
- LXRX 273.9M
- AVIR 247.5M
- IPO Year
- LXRX 2000
- AVIR 2020
- Fundamental
- Price
- LXRX $0.69
- AVIR $3.37
- Analyst Decision
- LXRX Buy
- AVIR Hold
- Analyst Count
- LXRX 2
- AVIR 1
- Target Price
- LXRX $6.00
- AVIR $6.88
- AVG Volume (30 Days)
- LXRX 5.0M
- AVIR 528.5K
- Earning Date
- LXRX 03-10-2025
- AVIR 02-26-2025
- Dividend Yield
- LXRX N/A
- AVIR N/A
- EPS Growth
- LXRX N/A
- AVIR N/A
- EPS
- LXRX N/A
- AVIR N/A
- Revenue
- LXRX $5,229,000.00
- AVIR N/A
- Revenue This Year
- LXRX $842.94
- AVIR N/A
- Revenue Next Year
- LXRX $19.76
- AVIR N/A
- P/E Ratio
- LXRX N/A
- AVIR N/A
- Revenue Growth
- LXRX 886.60
- AVIR N/A
- 52 Week Low
- LXRX $0.62
- AVIR $2.75
- 52 Week High
- LXRX $3.73
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- LXRX 40.93
- AVIR 55.56
- Support Level
- LXRX $0.70
- AVIR $3.11
- Resistance Level
- LXRX $0.75
- AVIR $3.60
- Average True Range (ATR)
- LXRX 0.08
- AVIR 0.13
- MACD
- LXRX -0.00
- AVIR 0.00
- Stochastic Oscillator
- LXRX 7.14
- AVIR 53.17
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).